Turning that into a mobile oper­a­tion is a prodi­gious task. The process has to be shrunk by more than a thou­sand­fold and sped up to work in less than 24 hours. And the drugs have to be tested in near-​​real time to prove they are safe, pure, and potent.

In addi­tion to MIT’s Center for Bio­med­ical Inno­va­tion, the project includes researchers from North­eastern Uni­ver­sity, Rens­se­laer Poly­technic Insti­tute, and indus­trial col­lab­o­ra­tors, such as Pall Corp., Perkin Elmer Inc., and Latham Bio­Pharm Group.

The team has promised that the biore­actor will be able to pro­duce two drugs within the next two years. If they meet that goal, the research will be eli­gible for a follow-​​up two-​​year grant to add four more drugs.

Read the article at The Boston Globe →